{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:56Z","timestamp":1791357116487,"version":"4.3.1"},"reference-count":36,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T00:00:00Z","timestamp":1432166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults ( n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with risperidone long-acting injectable therapy (RLAT) or conventional depot antipsychotics (APs). Treatment response was measured by change in Positive and Negative Syndrome Scale (PANSS) total score from baseline (BL) to last-observation-carried-forward (LOCF) endpoint (EP). Safety and tolerability assessments included Extrapyramidal Symptom Rating Scale (ESRS) total score and treatment-emergent adverse events. Significant reductions in mean PANSS total score were observed for all groups (\u22127.5 to \u221210.6; p \u2a7d 0.01 [BL to LOCF EP]). After switching to PP, more than 50% of all patients achieved \u2a7e20% and one-third of RLAT-treated patients even achieved \u2a7e50% improvement in PANSS total score. Across groups, there were significant improvements ( p &lt; 0.05) in symptom severity as measured by Clinical Global Impression-Severity (CGI-S; trend for improvement with RLAT; p = 0.0568), subjective well-being, medication satisfaction, and patient functioning with PP. PP was generally well tolerated. Clinically relevant benefits were observed in non-acute patients with schizophrenia switched from RLAT or conventional depot APs to PP.<\/jats:p>","DOI":"10.1177\/0269881115586284","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T20:45:38Z","timestamp":1432241138000},"page":"910-922","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics"],"prefix":"10.1177","volume":"29","author":[{"given":"A","family":"Schreiner","sequence":"first","affiliation":[{"name":"EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bergmans","sequence":"additional","affiliation":[{"name":"Biometrics & Reporting, Janssen Cilag Benelux, Tilburg, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Cherubin","sequence":"additional","affiliation":[{"name":"EMEA Medical Affairs, Janssen Cilag, Issy-les-Moulineaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Keim","sequence":"additional","affiliation":[{"name":"Global Clinical Operations EMEA Medical Affairs, Janssen Cilag, Barcarena, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P-M","family":"Llorca","sequence":"additional","affiliation":[{"name":"CHRU Clermont-Ferrand, H\u00f4pital Gabriel Montpied, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Cosar","sequence":"additional","affiliation":[{"name":"Gazi University Medical Faculty, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Petralia","sequence":"additional","affiliation":[{"name":"UOPI of Psychiatry, AOU Policlinico Vittorio Emanuele, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Corrivetti","sequence":"additional","affiliation":[{"name":"UOSM Distretto D, Pontecagnano-Faiano (Sa), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Hargarter","sequence":"additional","affiliation":[{"name":"EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"bibr1-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12201"},{"key":"bibr2-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1220740"},{"key":"bibr3-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp116"},{"key":"bibr4-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-012-0047-8"},{"key":"bibr5-0269881115586284","doi-asserted-by":"publisher","DOI":"10.2165\/11208640-000000000-00000"},{"key":"bibr6-0269881115586284","first-page":"233","volume":"7","author":"Chouinard G","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"bibr7-0269881115586284","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S17177"},{"key":"bibr8-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903482772"},{"key":"bibr9-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.10.022"},{"key":"bibr10-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2014.11.006"},{"key":"bibr11-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.05.014"},{"key":"bibr12-0269881115586284","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4088\/JCP.1107e27","volume":"68","author":"Kane JM","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"bibr13-0269881115586284","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12117tx1c"},{"key":"bibr14-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.195.52.s63"},{"key":"bibr15-0269881115586284","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12r08167"},{"key":"bibr16-0269881115586284","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"bibr17-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs150"},{"key":"bibr18-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.11.020"},{"key":"bibr19-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"bibr20-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub2"},{"key":"bibr21-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-834786"},{"key":"bibr22-0269881115586284","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.08r00612"},{"key":"bibr23-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-012-0604-8"},{"key":"bibr24-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835ba832"},{"key":"bibr25-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-8-32"},{"key":"bibr26-0269881115586284","unstructured":"National Institute for Health and Care Excellence (2014) Psychosis and schizophrenia in adults: Treatment and management. National Clinical Guideline Number CG178. Available at: http:\/\/www.nice.org.uk\/guidance\/cg178\/resources\/guidance-psychosis-and-schizophrenia-in-adults-treatment-and-management-pdf (accessed 19 February 2015)."},{"key":"bibr27-0269881115586284","volume-title":"Presented at 22nd European Congress of Psychiatry","author":"Romero Guillena SL","year":"2014"},{"key":"bibr28-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1177\/070674370605100808"},{"key":"bibr29-0269881115586284","first-page":"829","volume":"25","author":"Samtani MN","year":"2011","journal-title":"CNS Drugs"},{"key":"bibr30-0269881115586284","doi-asserted-by":"publisher","DOI":"10.2165\/11316870-000000000-00000"},{"key":"bibr31-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.08.014"},{"key":"bibr32-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000028"},{"key":"bibr33-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000133500.92025.20"},{"key":"bibr34-0269881115586284","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.7090su1cj"},{"key":"bibr35-0269881115586284","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033315"},{"key":"bibr36-0269881115586284","unstructured":"Xeplion SmPC (2015) Janssen."}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881115586284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881115586284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881115586284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:06:22Z","timestamp":1777507582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881115586284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1177\/0269881115586284"],"URL":"https:\/\/doi.org\/10.1177\/0269881115586284","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,21]]}}}